| 12404329 |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
John Desjarlais, Alex Nisthal, Matthew Adam Dragovich |
2025-09-02 |
|
| 12378326 |
Anti-CD28 x anti-PSMA antibodies |
John Desjarlais, Gregory Moore, Juan Diaz, Veronica Gusti Zeng, Matthew Adam Dragovich +6 more |
2025-08-05 |
|
| 12365743 |
Anti-CD28 x anti-PSMA antibodies |
John Desjarlais, Gregory Moore, Juan Diaz, Veronica Gusti Zeng, Matthew Adam Dragovich +6 more |
2025-07-22 |
|
| 12152076 |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon, Alex Nisthal +1 more |
2024-11-26 |
$22,601,000 |
| 12006345 |
Untargeted and targeted IL-10 Fc-fusion proteins |
Gregory Moore, Rajat Varma, Yoon Kyung Kim, Rumana Rashid, Alex Nisthal +2 more |
2024-06-11 |
$14,019,000 |
| 11932675 |
PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties |
John Desjarlais, Matthew Bernett, Rajat Varma, Suzanne Schubbert, Christine Bonzon +4 more |
2024-03-19 |
|
| 11919958 |
Anti-CD28 compositions |
John Desjarlais, Gregory Moore, Juan Diaz, Veronica Gusti Zeng |
2024-03-05 |
$7,091,000 |
| 11919956 |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
John Desjarlais, Alex Nisthal, Matthew Adam Dragovich |
2024-03-05 |
$7,091,000 |
| 11851466 |
Targeted IL-12 heterodimeric Fc-fusion proteins |
Matthew Bernett, John Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid +1 more |
2023-12-26 |
$10,740,000 |
| 11591401 |
Anti-CD28 compositions |
John Desjarlais, Gregory Moore, Juan Diaz, Veronica Gusti Zeng |
2023-02-28 |
$17,756,000 |
| 11492407 |
Bispecific checkpoint inhibitor antibodies |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon, Alex Nisthal +1 more |
2022-11-08 |
$17,695,000 |
| 11377477 |
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof |
Matthew Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rumana Rashid +1 more |
2022-07-05 |
$18,069,000 |
| 11312770 |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon, Alex Nisthal +1 more |
2022-04-26 |
$13,039,000 |
| 11236170 |
Bispecific checkpoint inhibitor antibodies |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon, Alex Nisthal |
2022-02-01 |
$16,959,000 |
| 10981992 |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon |
2021-04-20 |
$14,116,000 |
| 10793632 |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon |
2020-10-06 |
$31,498,000 |
| 10787518 |
Bispecific checkpoint inhibitor antibodies |
Matthew Bernett, Gregory Moore, John Desjarlais, Christine Bonzon, Alex Nisthal |
2020-09-29 |
$30,327,000 |
